Xeris Biopharma Holdings, Inc. (XERS)

Over the past six months, Xeris Biopharma's stock has been influenced by several events. The company reported record performance for Q4 and full year 2025 and provided 2026 guidance, announced inducement grants, and subsidiaries filed a patent infringement lawsuit related to Recorlev®. The company anticipated delivering record fourth-quarter and full-year 2025 total revenue. The stock price increased by 36.72% from April 9, 2025, to April 8, 2026, and experienced positive short-term returns, but a year-to-date decline. There has been net insider selling of company stock in the past three months.

The provided information does not explicitly detail any specific demand seasonality for Xeris Biopharma Holdings, Inc.'s products and services. The company experiences strong demand for key therapies, suggesting a consistent demand for its products.

Xeris Biopharma Holdings, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for chronic endocrine and neurological diseases, primarily in the United States. Their major commercial products include Recorlev® for Cushing's syndrome, Gvoke® for severe hypoglycemia, and Keveyis® for primary periodic paralysis. They are also advancing XP-8121 for hypothyroidism.

Xeris Biopharma Holdings, Inc. primarily focuses its commercialization efforts and operations within the United States, with its corporate headquarters located in Chicago, Illinois.

Xeris Biopharma Holdings, Inc. has shown positive indicators for its brand reputation, including reporting record performance for 2025 and strong demand for key therapies. Increasing institutional ownership suggests growing external validation. A patent infringement lawsuit was filed for Recorlev®, but its impact on brand reputation is not explicitly negative in the provided information.

Xeris Biopharma Holdings, Inc. has a diverse ownership structure. Institutional ownership is increasing, with major shareholders including BlackRock, Inc. and Vanguard Group Inc. Individual investors represent a significant portion of the company's shares. Insider ownership is also notable, with some insider buying activity offset by recent net insider selling.